Advertisement

Classification and characterization of anemia in cancer

  • M. R. Nowrousian

Abstract

Anemia can be defined as a condition of decreased red blood cell (RBC) mass, reflected in a decreased hemoglobin and hematocrit level. As a primary parameter, hemoglobin level is usually used to assess the severity of anemia and appears to be more precise than hematocrit level (Keen 1998). In healthy adults, hemoglobin levels range between 13.3–17.7 g/dl in men and 11.7–15.7 g/dl in women (Williams 1988; Fairbanks and Tefferi 2000). According to the World Health Organization, values below 13 g/dl in men and 12 g/dl in women are defined as anemia (World Health Organization 1968).

Keywords

Chronic Lymphocytic Leukemia Hemolytic Uremic Syndrome Thrombotic Thrombocytopenic Purpura Bone Marrow Infiltration Cold Agglutinin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abels R, Gordon D, Nelson R, Krantz K, Ageeb M, Goon B, Liebow B (1991) Transfusion practice in advanced cancer patients. Blood 78 (Suppl 1): 474aGoogle Scholar
  2. 2.
    Abels R, Larholt K, Nelson R, Young D (1994) Risk of transfusion in small cell lung cancer patients receiving chemotherapy. Blood 87 (Suppl): 664a (Abstr 2642 )Google Scholar
  3. 3.
    Alter R, Joshi SS, Verdirame JD, Weisenburger DD (1990) Pure red cell aplasia associated with B cell lymphoma: demonstration of bone marrow colony inhibition by serum immunoglobulin. Leuk Res 14: 279–286PubMedCrossRefGoogle Scholar
  4. 4.
    Barrett-Lee PJ, Bailey NP, O’Brien MER, Wager E (2000) Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82: 93–97PubMedCrossRefGoogle Scholar
  5. 5.
    Bay JO, Fouassier M, Beal D, Alcaraz L, Cure H, Chollet P, Plagne R, Travade P (1997) Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphocytic leukemia. Hematol Cell Ther 39: 209–212PubMedCrossRefGoogle Scholar
  6. 6.
    Braathen LR, Stavem P (1989) Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides. BMJ 298: 1713PubMedCrossRefGoogle Scholar
  7. 7.
    Canpolat C, Pearson P, Jaffe N (1994) Cisplatin-associated hemolytic uremic syndrome. Cancer 74: 3059–3062PubMedCrossRefGoogle Scholar
  8. 8.
    Cartwright GE (1966) The anemia of chronic disorders. Semin Hematol 3: 351–375PubMedGoogle Scholar
  9. 9.
    Chasty RC, Myint H, Oscier DG, Orchard JA, Bussutil DP, Hamon MD, Prentice AG, Copplestone JA (1998) Autoimmune haemolysis in patients with BCLL treated with chlorodeoxyadenosine ( CDA ). Leuk Lymphoma 29: 391–398Google Scholar
  10. 10.
    Coiffer B, Guastalla JP, Pujade-Lauraine E, Bastit P (2001) Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37: 1617–1623CrossRefGoogle Scholar
  11. 11.
    D’Elia JA, Aslani M, Schermer S, Cloud L, Bothe A, Dzik W (1987) Hemolyticuremic syndrome and acute renal failure in metastatic adenocarcinoma treated with mitomycin: case report and literature review. Ren Fail 10: 107–113PubMedCrossRefGoogle Scholar
  12. 12.
    Dessypris EN (1991) The biology of pure red cell aplasia. Semin Hematol 28: 275–284PubMedGoogle Scholar
  13. 13.
    Dighiero G (1996) Adverse and beneficial immunological effects of purine nucleoside analogues. Hematol Cell Ther 38 (Suppl 2): S75 - S81PubMedGoogle Scholar
  14. 14.
    Doll DC, Weiss RB (1985) Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep 69: 777–782PubMedGoogle Scholar
  15. 15.
    Fairbanks VF, Tefferi A (2000) Normal ranges for packed cell volume and hemoglobin concentration in adults: relevance to `apparent polycythemia’. Eur J Haematol 65: 285–296PubMedCrossRefGoogle Scholar
  16. 15a.
    Fleischman RA, Croy D (1995) Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia. Am J Hematol 48: 293PubMedCrossRefGoogle Scholar
  17. 16.
    Frenkel EP, Bick RL, Rutherford CJ (1996) Anemia of malignancy. Hematol Oncol Clin North Am 10: 861–873PubMedCrossRefGoogle Scholar
  18. 17.
    Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J (1999) A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85: 2023–2032PubMedGoogle Scholar
  19. 18.
    Garufi C, Vaglio S, Brienza S, Conti L, D’Attino RM, Girelli G, Terzoli E (2000) Immunohemolytic anemia following oxaliplatin administration. Ann Oncol 11: 497PubMedCrossRefGoogle Scholar
  20. 19.
    Gonzalez H, Leblond V, Azar N, Sutton L, Gabarre J, Binet JL, Vernant JP, Dighiero G (1998) Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 40: 113–118PubMedGoogle Scholar
  21. 20.
    Gordon LI, Kwaan HC (1997) Cancer-and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34: 140–147PubMedGoogle Scholar
  22. 21.
    Gordon LI, Kwaan HC (1999) Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost 25: 217–221PubMedCrossRefGoogle Scholar
  23. 22.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634PubMedCrossRefGoogle Scholar
  24. 23.
    Hamblin TJ, Orchard JA, Myint H, Oscier DG (1998) Fludarabine and hemolytic anemia in chronic lymphocytic leukemia. J Clin Oncol 16: 3209–3210PubMedGoogle Scholar
  25. 24.
    Hamner RW, Verani R, Weinman EJ (1983) Mitomycin-associated renal failure. Case report and review. Arch Intern Med 143: 803–807Google Scholar
  26. 25.
    Hanna WT, Krauss S, Regester RF, Murphy WM (1981) Renal disease after mitomycin C therapy. Cancer 48: 2583–2588PubMedCrossRefGoogle Scholar
  27. 26.
    Harrison LB, Shashy D, White C, Ramdeen B (2000) Radiotherapy-associated anemia: the scope of the problem. Oncologist 5 (Suppl 2): 1–7CrossRefGoogle Scholar
  28. 27.
    Juliusson G (1997) Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 39 (Suppl 1): S41 — S44PubMedCrossRefGoogle Scholar
  29. 28.
    Keen ML (1998) Hemoglobin and hematocrit: an analysis of clinical accuracy. Case study of the anemic patient. ANNA J 25: 83–86PubMedGoogle Scholar
  30. 29.
    Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, Sauerbruch T (1997) Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 96: 235–239PubMedCrossRefGoogle Scholar
  31. 30.
    Kwaan HC, Soff GA (1997) Management of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34: 159–166PubMedGoogle Scholar
  32. 31.
    Kwaan HC, Gordon LI (2001) Thrombotic microangiopathy in the cancer patient. Acta Haematol 106: 52–56PubMedCrossRefGoogle Scholar
  33. 32.
    Leach JW, Pham T, Diamandidis D, George JN (1999) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma ( Sezary syndrome ): A case report. Am J Hematol 61: 268–270Google Scholar
  34. 33.
    Lee GR (1983) The anemia of chronic disease. Semin Hematol 20: 61–80PubMedGoogle Scholar
  35. 34.
    Marani TM, Trich MB, Armstrong KS, Ness PM, Smith J, Minniti C, Sandler SG (1996) Carboplatin-induced immune hemolytic anemia. Transfusion 36: 1016 1018Google Scholar
  36. 35.
    Masaoka A, Hashimoto T, Shibata K, Yamakawa Y, Nakamae K, lizuka M (1989) Thymomas associated with pure red cell aplasia. Histologic and follow-up studies. Cancer 64: 1872–1878Google Scholar
  37. 36.
    Moake JL (1997) Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol 34: 83–89PubMedGoogle Scholar
  38. 37.
    Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, Hamon MD, Oscier DG, Hamblin TJ (1995) Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 91: 341–344PubMedCrossRefGoogle Scholar
  39. 38.
    Nordstrom B, Strang P (1993) Microangiopathic hemolytic anemias (MAHA) in cancer. A case report and review. Anticancer Res 13: 1845–1849Google Scholar
  40. 39.
    Nowrousian MR, Kasper C, Oberhoff C, Essers U, Voigtmann R, Gallasch W, Quarder O (1996) Pathophysiology of cancer-related anemia. In: Smyth JF, Boogaerts MA, Ehmer BRM (eds) rhErythropoietin in cancer supportive treatment. Marcel Dekker, New York, pp 13–34Google Scholar
  41. 40.
    Nowrousian MR (1998) Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 15 (Suppl 1): 19–28Google Scholar
  42. 41.
    Orchard J, Bolam S, Myint H, Oscier DG, Hamblin TJ (1998) In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy. Br J Haematol 102: 1112–1113PubMedCrossRefGoogle Scholar
  43. 42.
    Pujol M, Fernandez F, Sancho JM, Ribera JM, Milla F, Feliu E (2000) Immune hemolytic anemia induced by 6-mercaptopurine. Transfusion 40: 75–76PubMedCrossRefGoogle Scholar
  44. 43.
    Reiner AP, Spivak JL (1988) Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore) 67: 369–388Google Scholar
  45. 44.
    Robak T, Blasinska-Morawiec M, Krykowski E, Hellmann A, Konopka L (1997) Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 58: 109–113PubMedCrossRefGoogle Scholar
  46. 45.
    Rytting M, Worth L, Jaffe N (1996) Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 10: 365–376PubMedCrossRefGoogle Scholar
  47. 46.
    Sakai C, Takagi T, Wakatsuki S, Matsuzaki O (1995) Hemolytic-uremic syndrome due to deoxycoformycin: a report of the second case. Intern Med 34: 593–596PubMedCrossRefGoogle Scholar
  48. 47.
    Skillings JR, Sridhar FG, Wong C, Paddock L (1993) The frequency of red cell transfusion for anemia in patients receiving chemotherapy. Am J Clin Oncol 16: 22–25PubMedCrossRefGoogle Scholar
  49. 48.
    Skillings JR, Rogers-Melamed I, Nabholtz JM, Sawka C, Gwadry-Sridhar F, Moquin JP, Rubinger M, Ganguly P, Burnell M, Shustik C, Dryer D, McLaughlin M, White D, Mertens W (1995) An epidemiological review of anaemia in cancer chemotherapy in Canada. Eur J Cancer 31A (Suppl 5 ): S183 (Abstr 879)Google Scholar
  50. 49.
    Stone MJ, Frenkel EP (1975) The clinical spectrum of light chain myeloma. A study of 35 patients with special reference to the occurrence of amyloidosis. Am J Med 58: 601–619PubMedCrossRefGoogle Scholar
  51. 50.
    Susano R, Caminal L, Ferro J, Rubiales A, de Lera J, de Quiros JF (1994) [Microangiopathic hemolytic anemia associated with neoplasms: an analysis of 5 cases and a review of the literature]. Rev Clin Esp 194: 603–606Google Scholar
  52. 51.
    Tertian G, Cartron J, Bayle C, Rudent A, Lambert T, Tchernia G (1996) Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 38: 359–360PubMedCrossRefGoogle Scholar
  53. 52.
    Thatcher N (1998) Management of chemotherapy-induced anemia in solid tumors. Semin Oncol 25 (Suppl 7): 23–26PubMedGoogle Scholar
  54. 53.
    Tiziana M, Caligaris-Cappio (1997) Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 82: 375–381Google Scholar
  55. 54.
    Tsiara S, Christou L, Konstantinidou P, Panteli A, Briasoulis E, Bourantas KL (1997) Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia. Am J Hematol 54: 342PubMedCrossRefGoogle Scholar
  56. 55.
    Verwey J, de Vries J, Pinedo HM (1987) Mitomycin C-induced renal toxicity, a dose-dependent side effect? Eur J Cancer Clin Oncol 23: 195–199Google Scholar
  57. 56.
    Vick DJ, Byrd JC, Beal CL, Chaffin DJ (1998) Mixed-type autoimmune hemolytic anemia following fludarabine treatment in a patient with chronic lymphocytic leukemia/small cell lymphoma. Vox Sang 74: 122–126PubMedCrossRefGoogle Scholar
  58. 57.
    Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA (1999) Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 92: 153–160PubMedCrossRefGoogle Scholar
  59. 58.
    Walker RW, Rosenblum MK, Kempin SJ, Christian MC (1989) Carboplatinassociated thrombotic microangiopathic hemolytic anemia. Cancer 64: 1017 1020Google Scholar
  60. 59.
    Watson PR, Guthrie TH Jr, Caruana RJ (1989) Cisplatin-associated hemolyticuremic syndrome. Successful treatment with a staphylococcal protein A column. Cancer 64: 1400–1403Google Scholar
  61. 59a.
    Williams WJ (1988) Examination of the blood. Hematology. McGraw-Hill Book: New York, pp 9–21Google Scholar
  62. 60.
    Wood PA, Hrushesky WJ (1995) Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 95: 1650–1659PubMedCrossRefGoogle Scholar
  63. 60a.
    World Health Organization (1968) Nutritional Anemias. Reports of a WHO scientific group. GenevaGoogle Scholar
  64. 61.
    Wu DC, Liu JM, Chen YM, Yang S, Liu SM, Chen LT, Whang-Peng J (1997) Mitomycin-C induced hemolytic uremic syndrome: a case report and literature review. Jpn J Clin Oncol 27: 115–118PubMedCrossRefGoogle Scholar
  65. 62.
    Zucker S (1985) Anemia in cancer. Cancer Invest 3: 249–260PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  • M. R. Nowrousian
    • 1
  1. 1.Department of Internal Medicine (Cancer Research), West German Cancer CenterUniversity of Essen Medical SchoolEssenGermany

Personalised recommendations